

Curriculum Vitae - Prof. Dr. med. Dr. rer. nat. Ghazaleh Tabatabai

Personal Data

Title	Prof. Dr. med. Dr. rer. nat.
First name	Ghazaleh
Name	Tabatabai
Current position	Full Professor (W3, permanent)
Current institution(s)/site(s), country	Department of Neurology and Neuro-Oncology, University Hospital Tübingen, Tübingen, Germany
Identifiers/ORCID	0000-0002-3542-8782

Qualifications and Career

Stages	Periods and Details	
Degree program	1993 - 2000	Medicine (M.D.), Heinrich Heine University Düsseldorf
Doctorate	2005 - 2009	Doctor of Natural Sciences (Dr. rer. nat.), Doctoral program Graduate Training Center for Neuroscience Tübingen, Grade: <i>summa cum laude</i> .
	1999 - 2002	Doctor of Medicine (Dr. med), Heinrich Heine University Düsseldorf. Grade: <i>summa cum laude</i>
Stages of academic/professional career	2023 - 2026	Managing Clinical Director, Hertie Center for Neurology, University Hospital Tübingen
	2022 - 2024	Deputy Director (clinic), Comprehensive Cancer Center Tübingen-Stuttgart
	2022 - 2025	Chair of the structured DIAMOND mentoring program of the Neuro-Oncology Association for mentee in Germany, Austria and Switzerland
	Since 12/2019	Chair, Department of Neurology and Interdisciplinary Neuro-Oncology University Hospital Tübingen, Hertie Institute for Clinical Brain Research, University of Tübingen
	2019 - 2020	Vice Dean, Medical Faculty Tübingen
	2018 - 2020	Dean of Study Affairs, Molecular Medicine, Medical Faculty Tübingen
	2016 - 2018	Deputy Dean of Study Affairs, Molecular Medicine, Medical Faculty Tübingen
	2017 - 2019	Certificate of Advanced Studies “ <i>Systemic Management in Health Care</i> ”, University of St. Gallen, Switzerland
	2014 - 2019	Head, Division of Interdisciplinary Neuro-Oncology, Departments of Neurology & Neurosurgery University Hospital Tübingen
	Since 2014	Full Professor W3, Neuro-Oncology, University of Tübingen
	Since 2014	Research Group leader, Hertie Institute for Clinical Brain Research, University of Tübingen
	2009-2014	Research Group leader, Center for Neuroscience Zurich, ETH & University of Zurich

	2009-2014	Department of Neurology, University Hospital Zurich, Switzerland
	2011-2012	Certificate of Advanced Studies “ <i>Clinical Trials Management</i> ”, University of Zurich, Switzerland
	2012	Habilitation, Venia legend, Neurology, University of Zurich
	2009	Board certification, Neurology, Landesärztekammer Baden-Württemberg
	2003-2009	Residency Neurology, University Hospital Tübingen
	2001-2003	Residency Neuropathology, University Hospital Zurich
	2000-2001	Internship, Elective rotation in Neurology at Harvard Medical School, Boston, USA

Activities in the Research System

Committees and (inter)national boards (selection)

- 2024-2028 Chair, Expert Evaluation Committee (Fachkollegium) 206 Neuroscience, Deutsche Forschungsgemeinschaft
- 2020-2028 Member, Expert Evaluation Committee (Fachkollegium) 206 Neuroscience, Deutsche Forschungsgemeinschaft
- 2022-2024 Scientific Evaluation Committee, Institut National du Cancer, France
- Since 2021 CNS Tumors Faculty Group, European Society for Medical Oncology
- 2018-2022 Guideline Committee, European Association of Neuro-Oncology
- Since 2017 Executive Board, Center for Personalized Medicine Tübingen
- 2016-2024 Executive Board, Comprehensive Cancer Center Tübingen
- 2015-2020 Neuro-Oncology Committee, World Federation of Neurosurgical Societies

Coordination of joint funding programs and clinical trials

- Since 2023 International Coordinator/Lead Principal Investigator, CV-GBLM001 trial, phase 1 (NCT05938387), Sponsor: CureVac
- Since 2021 Sponsor delegate/Principal investigator, Investigator-initiated phase 1 trial NOA26/IT-PD1 (NCT05112549), Sponsor: University Hospital Tübingen
- 2021-2025 Sponsor delegate/Principal investigator, Investigator-initiated phase 1 trial GlioXS15 (NCT04842513), Sponsor: University Hospital Tübingen
- 2017-2024 Spokesperson/Lead Principal Investigator, Else Kröner-Forschungskolleg Tübingen, “Acquired resistance to therapy in solid tumors” (two funding periods)

Ad hoc referee for scientific journals (selection)

Acta Neuropathologica, Annals of Oncology, Brain, Clinical Cancer Research, European Journal of Cancer, Molecular Cancer, Neuro-Oncology, Nature Medicine, Lancet Oncology

Ad hoc referee for funding agencies and organizations (selection)

Cancer Research UK (GB), Yorkshire Cancer Center (GB), Oncosuisse (CH), Institut National du Cancer (F), Agence Nationale de la Recherche (F), ZonMW (Niederlande), Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft.

Supervision of Researchers in Early Career Phases

- **Supervision of Postdoctoral Researchers and Clinician Scientists**

Supervision of 3 Postdoctoral researchers (2 female, 1 male), 6 Clinician Scientists (3 female, 3 male)

- **Supervision of PhD students**

4 PhD students completed (3 x Dr. rer. nat, summa cum laude / 1 x Dr. sc. nat, magna cum laude, 3 female, 1 male), 4 PhD students currently ongoing (2 female, 2 male).

- **Supervision of Medical Students**

2 MD completed with experimental work in the lab (summa cum laude, magna cum laude), and 10 MD students with clinical work (1 x magna cum laude, 9 x cum laude), 8 MD students currently ongoing (7 experimental work in the lab, 1 clinical study).

- **Supervision of Master students and Bachelor Students**

4 Master theses completed, 7 Bachelor theses completed

Scientific Results

Category A: Ten selected publications as main author

* First author, ** senior author, [OA]: open access

1. ** Haeusser LA, Becker H, Kuhlburger L, Zago M, Walter B, Tsiami F, Erdmann S, Trampert J, Surender S, Stahl A, Templin M, Wegner E, Schmidt T, Schmees C, Casadei N, Sevenich L, Claassen M, Nahnsen S, Beck S, Merk DJ, **Tabatabai G**. "Genome-wide CRISPR-Cas9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma". **Neuro Oncol.** **2025**; 27(4):916-931. doi: 10.1093/neuonc/noae278. [OA]
2. ** Merk DJ, Tsiami F, Hirsch S, Walter B, Haeusser LA, Maile JD, Stahl A, Jarboui MA, Lechado-Terradas A, Klose F, Babaei S, Admard J, Casadei N, Roggia C, Spohn M, Schittenhelm J, Singer S, Schüller U, Piccioni F, Persky NS, Claassen M, Tatagiba M, Kahle PJ, Root DE, Templin M, **Tabatabai G**. "Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors". **Genome Biol.** **2024**; 25(1):301. doi: 10.1186/s13059-024-03438-w. [OA]
3. ** Merk DJ, Paul L, Tsiami F, Hohenthanner H, Kouchesfahani GM, Haeusser LA, Walter B, Brown A, Persky NS, Root DE, **Tabatabai G**. "CRISPR-Cas9 screens reveal common essential miRNAs in human cancer cell lines". **Genome Med J**, **2024**;16(1):82. doi: 10.1186/s13073-024-01341-4 [OA]
4. ** Walter B, Hirsch S, Kuhlburger L, Stahl A, Schnabel L, Wisser S, Haeusser LA, Tsiami F, Plöger S, Aghaallaei N, Dick AM, Skokowa J, Schmees C, Templin M, Schenke-Layland K, Tatagiba M, Nahnsen S, Merk DJ, **Tabatabai G**. "Functionally-instructed modifiers of response to ATR inhibition in experimental glioma". **Journal of Experimental & Clinical Cancer Research**, **2024**; 43(1):77. doi: 10.1186/s13046-024-02995-z [OA]
5. ** Trautwein C, Zizmare L, Mäurer I, Bender B, Bayer B, Ernemann U, Tatagiba M, Grau SJ, Pichler BJ, Skardelly M, **Tabatabai G**. "Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment". **JCI Insight**, **2022**; 7(3). doi: 10.1172/jci.insight.153526. [OA]
6. ** Behling F, Fodi C, Gepfner-Tuma I, Kaltenbach K, Renovanz M, Paulsen F, Skardelly M, Honegger J, Tatagiba M; International Consortium on Meningiomas; Schittenhelm J^S,

Tabatabai G[§]. “H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort”.

Neuro-Oncology, 2021; 23(8): p. 1273-81. doi: 10.1093/neuonc/noaa303. [OA] (♦co-senior authors)

7. ** Wick A, Bähr O, Schuler M, Rohrberg K, Chawla SP, Janku F, Schiff D, Heinemann V, Narita Y, Lenz HJ, Ikeda M, Ando Y, Wick W, Steinbach JP, Burger MC, Wenger K, Lassen U, Sankhala KK, Roggia C, Genvresse I, Munhoz C, Rentzsch C, Reschke S, Langer S, Wagner M, Kaulfuss S, Cai C, Lagkadinou E, Jeffers M, Peña C, **Tabatabai G.** “Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors”.
Clinical Cancer Research, 2021; 27(10): p. 2723-33. doi: 10.1158/1078-0432.Ccr-20-4256
8. * Weller M[♦], **Tabatabai G[♦]**, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G[§], Wick W[§]. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Clinical Cancer Research, 2015; 21(9): p. 2057-64. doi: 10.1158/1078-0432.Ccr-14-2737 (♦co-shared first authors, §co-shared senior authors)
9. ** Wirsching HG, Krishnan S, Florea AM, Frei K, Krayenbühl N, Hasenbach K, Reifenberger G, Weller M, **Tabatabai G.** “Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma”.
Brain , 2014; 137(Pt 2): p. 433-48. doi: 10.1093/brain/awt333
10. ** Hasenbach K, Wiehr S, Herrmann C, Mannheim J, Cay F, von Kürthy G, Bolmont T, Grathwohl SA, Weller M, Lengerke C, Pichler BJ, **Tabatabai G.** “Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomography”.
Neuro-Oncology, 2012; 14(4): p. 471-81. doi: 10.1093/neuonc/nor228

Category B

Ongoing Patent Applications: ENFORCING-GB (5402P681), UNRAVEL-GB (5402P686), IMPACT-GB (5402P687), INTERVENE-GB (5402P690), INTEGRATE (5402P672EP), Therapeutic Agent for Cancer MeP-Gli-01 (5402P578EP)

Curriculum Vitae – Prof. Dr. med. Nisar Peter Malek

Personal Data

Title	Prof. Dr. med.
First name	Nisar Peter
Name	Malek
Current position	Full Professor (W3, permanent); Chair/Director, Dept. of Internal Medicine I (Gastroenterology, Hepatology, Infectiology, GI Oncology, Geriatrics)
Current institution(s)/site(s), country	University Hospital and Faculty of Medicine Tübingen, Tübingen, Germany
Identifiers/ORCID	ORCID: n/a; Wikipedia: https://de.wikipedia.org/wiki/Nisar_Peter_Malek

Qualifications and Career

Stages	Periods and Details	
Degree program	1989-1996	Medicine, Hannover Medical School (MHH) (as stated in summary)
Doctorate	03/1996	Doctor of Medicine (Dr. med.), Hannover Medical School (MHH). Doctoral thesis 10/1991-09/1993, Institute of Molecular Biology, MHH (Prof. Alfred Nordheim).
Stages of academic/professional career	1998 - 2001	Postdoctoral Fellow (DFG training grant), Fred Hutchinson Cancer Research Center, Seattle, WA, USA (Prof. James M. Roberts).
	02/2001	Scientific assistant, Dept. of Gastroenterology, Hepatology and Endocrinology, MHH (Prof. M. P. Manns) and Group leader, Institute of Molecular Biology, MHH (Prof. Achim Gossler).
	10/2002	Head of working group, Max Eder Program, German Cancer Aid (Phase 1: 2002-2005; Phase 2: 2005-2008)
	01/2004	Project leader, DFG Clinical Research Unit 119: “Molecular basis and consecutive therapeutic approaches in hepatocellular carcinoma”
	04/2006	Specialist in Internal Medicine
	10/2006	Senior physician, Dept. of Gastroenterology, Hepatology and Endocrinology, MHH
	05/2007	Venia legendi (Internal Medicine), Hannover Medical School
	01/2007	Head, working group “Cell Proliferation Control”, DFG Cluster of Excellence REBIRTH
	01/2007	Head, TransMedLab, Helmholtz Centre for Infection Research, Braunschweig
	05/2007	Project leader, SFB 738 “Optimization of conventional and innovative transplants”
	11/2007	Spokesman, AG Drug Development Phase I/II Studies, Association of Internal Oncology (AIO)

	02/2008	Professor (W2) "Cell Proliferation Control", DFG Cluster of Excellence REBIRTH, MHH
	01/2009	Additional qualification in Gastroenterology
	01/2010	Project leader, TR77 "Liver Cancer from Molecular Pathogenesis to Targeted Therapies"
	since 09/2011	Full Professor and Director/Chair, Internal Medicine I (Gastroenterology, Hepatology, Infectiology), University Hospital Tübingen
	since 04/2012	Member, Executive Board, Department of Internal Medicine, University Hospital Tübingen
	08/2013	Deputy Director, Comprehensive Cancer Center (CCC) Tübingen
	Since 01/2015	Chairman of the Board, Center for Personalized Medicine (ZPM) Tübingen; Platform 1, Excellence Initiative, University of Tübingen
	Since 01/2015	Spokesman, ZPM Network Baden-Württemberg.
	Since 10/2015	Managing Director, Department of Internal Medicine, University Hospital Tübingen
	Since 01/2017	Founding Director, M3 Research Institute, University Hospital Tübingen
	01/2017-2022	Co-Speaker, DFG Collaborative Research Center Liver Cancer
	Since 01/2019	Spokesperson, ZPM network in the state advisory board "Personalized Medicine"
	Since 01/2021	Consortium leader, German Network Personalized Medicine (DNPM)

Activities in the Research System

Committees and (inter)national boards (selection)

Since 2012 Member, Scientific Advisory Board, Comprehensive Cancer Center Göttingen.

Since 2012 Member, Advisory Board, Cancer Center Toulouse.

Since 2012 Member, Board of Trustees, Fritz Lipmann Institute for Ageing Research, Jena.

2014-2024 Member, Expert Committee "Medical and Scientific Promotion of Young Researchers", German Cancer Aid.

Since 2015 Chairman, Commission "Science and Promotion of Young Researchers", German Society for Internal Medicine (DGIM).

Since 01/2021 Member, Steering Committee "genom.de", Federal Ministry of Health.

Since 01/2022 Spokesperson, interministerial working group Baden-Württemberg "Standardization of data and data access".

Since 01/2022 Commission spokesperson, German Cancer Society (DKG) Certification Commission for Centers for Personalized Medicine.

Supervision of Researchers in Early Career Phases

• *Supervision of Postdoctoral Researchers and Clinician Scientists*

Supervision of 6 Postdoctoral researchers (2 female, 4 male), 6 Clinician Scientists (3 female, 3 male)

• *Supervision of PhD students*

>10 PhD students completed

- *Supervision of Medical Students*
>10 MD thesis completed
- *Supervision of Master students and Bachelor Students*
5 Master thesis completed

Scientific Results

Category A

* First author, ** senior author, [OA]: open access

1. ** Illert AL, Stenzinger A, Bitzer M, [...], **Malek NP**. "The German Network for Personalized Medicine to Enhance Patient Care and Translational Research". **Nature Medicine**, 2023; 29(6):1298-1301. doi:10.1038/s41591-023-02354-z
2. ** Bitzer M, Spahn S, Babaei S, [...], **Malek NP**. "Targeting Extracellular and Juxtamembrane FGFR2 Mutations in Chemotherapy-Refractory Cholangiocarcinoma". **NPJ Precision Oncology**, 2021; 5:80. doi:10.1038/s41698-021-00220-0
3. ** Bitzer M, Ostermann L, Horger M, Biskup S, Schulze M, Ruhm K, Hilke F, Öner Ö, Nikolaou K, Schroeder C, Riess O, Fend F, Zips D, Hinterleitner M, Zender L, Tabatabai G, Beha J, **Malek NP**. "Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options". **JCO Precision Oncology**, 2020; 4. doi:10.1200/PO.19.00359
4. ** Zender S, Nicleleit I, Wuestefeld T, Sörensen I, Dauch D, Bozko P, El-Khatib M, Geffers R, Bektas H, Manns MP, Gossler A, Wilkens L, Plentz R, Zender L, **Malek NP**. "A Critical Role for Notch Signaling in the Formation of Cholangiocellular Carcinomas". **Cancer Cell**, 2013; 23(6):784-795. doi:10.1016/j.ccr.2013.04.019
5. ** Puklowski A, Homsy Y, Keller D, May M, Chauhan S, Kossatz U, Grünwald V, Kubicka S, Pich A, Manns MP, Hoffmann I, Gönczy P, **Malek NP**. "The SCF-FBXW5 E3-Ubiquitin Ligase Is Regulated by PLK4 and Targets HsSAS-6 to Control Centrosome Duplication". **Nature Cell Biology**, 2011; 13(8):1004-1009. doi:10.1038/ncb2282.
6. ** Nicleleit I, Zender S, Sasse F, Geffers R, Brandes G, Sörensen I, Steinmetz H, Kubicka S, Carlomagno T, Menche D, Gütgemann I, Buer J, Gossler A, Manns MP, Kalesse M, Frank R, **Malek NP**. "Argyris A Reveals a Critical Role for the Tumor Suppressor Protein p27(Kip1) in Mediating Antitumor Activities in Response to Proteasome Inhibition". **Cancer Cell**, 2008; 14(1):23-35. doi:10.1016/j.ccr.2008.05.016
7. ** Timmerbeul I, Garrett-Engle CM, Kossatz U, Chen X, Firpo E, Grünwald V, Kamino K, Wilkens L, Lehmann U, Buer J, Geffers R, Kubicka S, Manns MP, Porter PL, Roberts JM, **Malek NP**. "Testing the Importance of p27 Degradation by the SCF-SKP2 Pathway in Murine Models of Lung and Colon Cancer". **Proc Natl Acad Sci U S A**, 2006;103(38):14009-14014. doi:10.1073/pnas.0606316103
8. ** Kossatz U, Vervoorts J, Nicleleit I, Sundberg HA, Arthur JS, Manns MP, **Malek NP**. "C-Terminal Phosphorylation Controls the Stability and Function of p27Kip1". **EMBO Journal**, 2006; 25(21):5159-5170. doi:10.1038/sj.emboj.7601388
9. ** Kossatz U, Dietrich N, Zender L, Buer J, Manns MP, **Malek NP**. "Skp2-Dependent Degradation of p27kip1 Is Essential for Cell Cycle Progression". **Genes & Development**, 2004; 18(21):2602-2607. doi:10.1101/gad.321004.

10. * **Malek NP**, Sundberg H, McGrew S, Nakayama K, Kyriakides TR, Roberts JM. "A Mouse Knock-in Model Exposes Sequential Proteolytic Pathways That Regulate p27Kip1 in G1 and S Phase".
Nature, 2001; 413(6853):323-327. doi:10.1038/35095083.

Ongoing Patent Applications

- ARGYRIN-GB (ARG-PCT-1), **US8217071B2 / EP2120929B1 / WO2010006682A1**
- PROTEASOME-GB (PROT-INT-1), **US9458200B2**
- CELL-GROWTH-GB (GROWTH-US-1), **US7435591B2**

Prizes and Awards

2008 Science Prize of the Association of Internal Oncology (AIO).

2009 Johann-Georg-Zimmermann Prize for Cancer Research (donated by Deutsche Hypothekenbank)

Memberships

German Society for Internal Medicine (DGIM).

German Society for Digestive and Metabolic Diseases (DGVS).

German Cancer Society (DKG).

Working Group for Internal Oncology (AIO).

Curriculum Vitae - Univ. Prof. Dr. rer. nat. Mathias Heikenwälder

Personal Data

Title	Univ. Prof. Dr. rer. nat.
First name	Mathias
Name	Heikenwälder
Current positions	Full Professor (W3, permanent)
Current institution/site, country	The M3 Research Center, University Hospital Tübingen, Tübingen, Germany
Identifiers/ORCID	0000-0002-3135-2274

Qualifications and Career

Stages	Periods and Details
Degree program	1994 - 1999 Studies of Microbiology and Genetics, Max-Perutz Laboratories and Institute of Molecular Pathology, University of Vienna, Austria
Doctorate	2000 - 2004 Ph.D. Thesis, Institute of Neuropathology, University Hospital Zurich, Switzerland. Grade: <i>summa cum laude</i>
Stages of academic/ professional career	Since 10/2022 Scientific/Executive director of The M3 Research Center, University of Tübingen Since 10/2022 Full Professor W3, University of Tübingen Since 2015 DKFZ, Head of the division "Chronic inflammation and cancer", Heidelberg, Germany 2015 - 2022 Full Professor W3, University of Heidelberg 2010 - 2015 W2-Professor, TU München 2010 - 2015 Helmholtz Young Group Investigator, Helmholtz-Zentrum München 2010 - 2015 Peter-Hans Hofschneider Professor for Chronic inflammation and Cancer, Stiftung Experimentelle Medizin 2009 Habilitation and Venia Legendi in Experimental Pathology, Medical Faculty, University Hospital Zürich, Switzerland (mentor Prof. Dr. Holger Moch; Prof. François Verrey) 2007-2010 Prof. Dr. Max-Cloëtta fellow (Ass. Prof.) and independent group leader, Department of Pathology and start as a principal investigator, University of Zurich, Switzerland 2006 Staff scientist and lecturer, Department of Pathology, Institute of Neuropathology, University of Zurich, Switzerland 2004 Postdoctoral fellow, Institute of Neuropathology, Pathology Department, University Hospital Zurich, Switzerland

Activities in the Research System

Committees and (inter)national boards (selection)

- Since 2023 Executive Board, Comprehensive Cancer Center Tübingen.
Since 2022 External Scientific Advisory Board, NIHR Birmingham BRC, UK.
Since 2020 Scientific Advisory Board, PSC/PBC program, Mayo Clinic, Rochester, USA.
Since 2024 Scientific Advisory Board, Deutsche Krebshilfe, Bonn.
Since 2018 Scientific Advisory Board, Peter-Hans Hofschneider Stiftung, Zurich, Switzerland.

Coordination of joint funding programs and organizer of scientific meetings

- 2025 Organizer of the Digestive Disease Mechanism (DDM) Summit at UEG, Berlin.
2023 Organizer of the EASL Liver Cancer Summit Estoril, Portugal.
2022 Organizer of the Scientific Summit, EASL conference, London, UK.
2017 - 2022 Scientific co-coordinator of the Helmholtz Alliance "Inflammation and Immunity", German Cancer Research Center, Heidelberg.

Scientific management education

- 2021 - 2022 Helmholtz Circle Advanced Management Course, Helmholtz Academy, Berlin.
2011 - 2013 Certified "Science Manager", Malik Management School, St. Gallen, Switzerland and Helmholtz academy for leadership.

Ad hoc referee for scientific journals (selection)

Nature, Nature Immunology, Nature Metabolism, Nature Medicine, Nature Cell Biology, Nature Methods, Nature Communications, Cell Metabolism, Cell, Science, Lancet Oncology, Cancer Research, Cancer Discovery.

Ad hoc referee for funding agencies and organizations (selection)

Cancer Research UK (GB), Swiss National Foundation (SNF), Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft.

Supervision of Researchers in Early Career Phases

- *Supervision of Postdoctoral Researchers and Clinician Scientists*
12 postdoctoral researchers (7 male, 6 female), 5 Clinician scientists (3 male, 2 female)
- *Supervision of PhD students*
21 PhD students completed (10 male, 11 female)
- *Supervision of Master students and Bachelor Students*
8 Master students (5 male, 3 female), 4 Bachelor students (3 male, 1 female)

Scientific Results

Category A

** senior author, §co-shared senior authors

1. ** Li X, Lebeaupin C, Kadianaki A, [...], Kaufmann R[§], **Heikenwalder M[§]**. „Chronically activated ATF6α is a hepatic tumor-driver metabolically restricting immunosurveillance". **Nature**, 2026 January, in press.
2. ** Kommos KS, Krishnarajah S, Bieler T, Friebel E, Rindlisbacher L, Ramadori P, Häne P, Kam S, Müller F, Prokosch S, Rothermel U, Wu Y, Barletta F, Czernmel S, Nahnsen S, Helm D, Schneider M, Schäkel K, Enk A, Becher B, **Heikenwälder M.** „Single cell mapping identifies a distinct platelet-phenotype in psoriatic type III inflammation". **Nature Communications**, **2025**;16(1):10881. doi: 10.1038/s41467-025-65894-7.
3. ** Gallage S, Ali A, Barragan Avila JE, Seymen N, Ramadori P, Joerke V, Zizmare L, Aicher D, Gopalsamy IK, Fong W, Kosla J, Focaccia E, Li X, Yousuf S, Sijmonsma T, Rahbari M, Mathias Heikenwälder

- Kommoss KS, Billeter A, Prokosch S, Rothermel U, Mueller F, Hetzer J, Heide D, Schinkel B, Machauer T, Pichler B, Malek NP, Longerich T, Roth S, Rose AJ, Schwenck J, Trautwein C, Karimi MM, **Heikenwalder M**. “A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPAR α and PCK1”.
Cell Metabolism, **2024**; 36(6):1371-1393.e7. doi: 10.1016/j.cmet.2024.04.015
4. ** Pfister D, Núñez NG, Pinyol R, [...], Llovet JM[§], **Heikenwalder M[§]**. „NASH limits anti-tumour surveillance in immunotherapy-treated HCC”.
Nature, **2021**; 592(7854): 450-456. doi: 10.1038/s41586-021-03362-0.
 5. ** Conlon TM, John-Schuster G, Heide D, [...], Königshoff M, **Heikenwalder M***, Yildirim AÖ*. „Inhibition of LT β R signalling activates WNT-induced regeneration in lung”.
Nature, **2020**; 588(7836): 151-156. doi: 10.1038/s41586-020-2882-8.
 6. O'Connor T, Zhou X, Kosla J, [...], Keller U, **Heikenwalder M**. “Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention”.
Cancer Cell, **2019**; 36(3): 250-267.e9. doi: 10.1016/j.ccell.2019.08.001.
 7. ** Malehmir M, Pfister D, Gallage S, [...], Unger K, Zender L, Nieswandt B, Gawaz M, Weber A[§], **Heikenwalder M[§]**. “Platelet GPIIb α is a mediator and potential interventional target for NASH and subsequent liver cancer”.
Nature Medicine, **2019**; 25(4): 641-655. doi: 10.1038/s41591-019-0379-5.
 8. ** Lorentzen A, Becker PF, [...], Borsig L, **Heikenwalder M**. “Single cell polarity in liquid phase facilitates tumour metastasis”.
Nature Communications, **2018**; 9(1): 887. doi: 10.1038/s41467-018-03139-6.
 9. ** Yuan D, Huang S, Berger E, Pikarsky E, Hüser N, Davis RJ, Tschaharganeh DF, Rad R, Weber A, Zender L, Haller D[§], **Heikenwalder M[§]**. “Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS”.
Cancer Cell, **2017**; 31(6): 771-789.e6. doi: 10.1016/j.ccell.2017.05.006.
 10. ** Wolf MJ, Adili A, Piotrowitz K, [...], Knolle P*, Weber A*, **Heikenwalder M[§]**. “Metabolic activation of intrahepatic CD8⁺ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes”.
Cancer Cell, **2014**; 26(4): 549-564. doi: 10.1016/j.ccell.2014.09.003.

Category B

Heikenwälder M, Zender L, EP000003475425A1 Treatment of non-alcoholic steato-hepatitis (NASH)

Academic Distinctions, prizes

2026-2031	ERC Synergy grant “Hepatomodulator”
2018-2025	Most highly cited researcher (“Cross Topic” Web of Science)
2024-2028	EU Horizon Grant “THRIVE” (Co-Coordinator)
2022	German Cancer Award
2020-2021	ERC Proof of concept (POC) grant
2019	Elected Member of the Leopoldina, Section XIV
2018	Swiss Prize for Liver Gastroenterology
2015-2020	ERC Consolidator Grant
2012	Walther and Christine Richtzenhain Award, DKFZ, Heidelberg;

2010-2015	ERC Starting Grant
2009	Götz Prize, University of Zurich, Switzerland.
2006	Empiris Award for brain research, Empiris foundation for brain research, Zurich Switzerland
2004	Research grant from the University of Zurich, Switzerland, to initiate an independent research group
2004	Creutzfeldt Science Prize, Creutzfeldt-Stiftung, Kiel
1999-2000	Erasmus scholarship from the European Community and merit-based scholarship from the University of Vienna, Austria

Curriculum Vitae - Prof. Dr. med. M.Sc. M.Sc. MME MBA André Leopold Mihaljevic

Personal Data

Titel	Prof. Dr. med. M.Sc. M.Sc. MME MBA
First name	André Leopold
Name	Mihaljevic
Current Position	Chairman, Department of General, Visceral and Transplant Surgery, University Hospital Tübingen
Current institution(s)/site(s), country	Universitätsklinikum Tübingen, Hoppe-Seyler-Str. 3 72076 Tübingen
Identifiers/ORCID	0000-0003-1902-657X

Qualifications and Career

Stages	Periods and Details	
School	1997 - 1998	Civil Service at the Centro Diaconale "la noce", Istituto Valdese, Palermo, Italy
	1997	Abitur, Altes Kurfürstliches Gymnasium Bensheim, Germany
Degree program	2005	Humanmedizin; Ruprecht-Karls Universität Heidelberg
	2004	Master of Science (M.Sc) in Molecular and Cellular Biology; Ruprecht-Karls Universität Heidelberg
	2019	Master of Science (M.Sc.) in Clinical Research and Translational Medicine, Universität Leipzig
	2021	Master of Business Administration (MBA), Wirtschaftsuniversität Wien (WU Wien)
	2022	Master of Medical Education (MME), Ruprecht-Karls Universität Heidelberg
Doctorate	2007	Promotion („Analysis of recombinant glutamate receptors in the hippocampus of the mouse“ magna cum laude), Max-Planck-Institut für Medizinische Forschung, Ruprecht-Karls-Universität Heidelberg
Stages of academic/professional career	since 07/2023	Chairman, Department of General, Visceral and Transplant Surgery, University Hospital Tübingen
	10/2020 - 06/2022	Head of the Clinical Trials Unit, Department of Surgery, University Hospital Ulm
	since 2022	Speaker of the Surgical Clinical Trial Network CHIR-Net of the German Surgical Society (CHIR-Net)
	10/2020 - 06/2022	Vice Chairman, Department of General and Visceral Surgery, University Hospital Ulm

	2021	Fellow of the European Board of Surgeons (FEBS) in Surgical Oncology
	2019- 2021	Board Member of IP-Health (Gesellschaft für Interprofessionelle Gesundheitsversorgung e.V.)
	2019	Board Certification „spezielle Viszeralchirurgie“
	since 2017	Founding scientist and speaker of the Research Group „Forschungspartnerschaft“ for patient centred clinical research
	since 2017	Founding scientist and speaker of the Research Group student-led Clinical Trial Network SIGMA (Student-Initiated German Medical Audit)
	09/2017	Board Certification “Proctology”
	08/2017	Board Certification “Visceral Surgery”
	07/2015 – 09/2020	Attending Surgeon, Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital
	2014-2020	Coordinator HeiCuMed (Heidelberger Curriculum Medicinale) for the surgical disciplines (Block II)
	07/2014-06/2015	Facharzt Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital (Prof. Dr. M. W. Büchler)
	2013 - 2022	Vice-Speaker of the Surgical Clinical Trial Network CHIR-Net of the German Surgical Society (CHIR-Net)
	2013	Board Certification “General Surgery”
	10/09/2012	Board Certification “Notfallmedizin”
	2012-2014	Head of CHIR-Net regional centre Munich
	11/2008 – 11/2009	Traumatology rotation at Romed Klinikum Prien am Chiemsee
	07/2007 – 06/2014	Surgical residency, Klinik und Poliklinik des Klinikums rechts der Isar der Technischen Universität München
	07/2006 – 06/2007	Surgical residency, Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital
	2003- 2004	Master thesis “mRNA trafficking of the voltage-gated potassium channel subunit Kv4.2 in hippocampal pyramidal neurons” National Institutes of Health (NIH), Bethesda MD, USA, Laboratory of Cellular and Synaptic Neurophysiology

Activities in the Research System

- since 2022 Member, Expert Evaluation Committee “Investigator-Initiated Clinical Trials” of the Swiss National Foundation (SNF)
- since 2022 Speaker of the Surgical Clinical Trial Network of the German Surgical Society CHIR-Net
- since 2023 Member, Board of Advisors, Belgium Anticancer Fund

Supervision of Researchers in Early Career Phases

Founding member of the Heidelberg Graduate School of Surgery (<https://www.graduate-school-heidelberg.university/>) 2017-2020.

Scientific Results (*Focus on medical education and patient centred research*) Category A

* First author, ** senior author, [OA]: open access

1. ** Kuner C, Doerr-Harim C, Feißt M, Klotz R, Heger P, Probst P, Strothmann H, Götsch B, Schmidt J, Mink J, Mitzkat A, Trierweiler-Hauke B, **Mihaljevic AL**. “Clinical outcomes of patients treated on the Heidelberg interprofessional training ward vs. care on a conventional surgical ward: A retrospective cohort study”.
Jornal of Interprofessional Care, 2022; 36:552-559. doi: 10.1080/13561820.2021.1975667
2. * **Mihaljevic AL**; CHIR-Net SIGMA Study Group. “Postoperative Complications and Mobilization Following Major Abdominal Surgery With Versus Without Fitness Tracker-based Feedback (EXPELLIARMUS): A Student-led Multicenter Randomized Controlled Clinical Trial of the CHIR-Net SIGMA Study Group”.
Annals of Surgery, 2024; 280(2):202-211. doi: 10.1097/SLA.0000000000006232
3. ** CHIR-Net SIGMA Study Group*; **Mihaljevic AL**. “Multicenter Prospective Cohort Study of the Patient-Reported Outcome Measures PRO-CTCAE and CAT EORTC QLQ-C30 in Major Abdominal Cancer Surgery (PATRONUS): A Student-Initiated German Medical Audit (SIGMA) Study”.
Annals of Surgical Oncology, 2021; 28(6):3075-3089. doi: 10.1245/s10434-021-09646-z
4. ** Klotz R, Holze M, Dörr-Harim C, Grohmann E, Nied B, Lebert B, Weg-Remers S, Lutz C, Meißler K, Schloss P, Ullrich C, Frankenhauser S, Lutter H, Bühler D, Ahmed A, Gronlund T, **Mihaljevic AL**; Forschungspartnerschaft Darmkrebs (www.forschungspartnerschaft.de); Steering Group Forschungspartnerschaft Darmkrebs/Priority Setting Colorectal Cancer. “Top 10 research priorities in colorectal cancer: results from the Colorectal Cancer Priority-Setting Partnership”.
Journal of Cancer Research and Clinical Oncology, 2023; 149(4):1561-1568. doi: 10.1007/s00432-022-04042-w
5. Klotz R, Doerr-Harim C, Ahmed A, Tjaden C, Tarpey M, Diener MK, Hackert T, **Mihaljevic AL**; Priority Setting Partnership Pancreatic Cancer. “Top ten research priorities for pancreatic cancer therapy”.
Lancet Oncology, 2020; 21(6):e295-e296. doi: 10.1016/S1470-2045(20)30179-0.
6. Klotz R, **Mihaljevic AL**, Kulu Y, Sander A, Klose C, Behnisch R, Joos MC, Kalkum E, Nickel F, Knebel P, Pianka F, Diener MK, Büchler MW, Hackert T. “Robotic versus open partial

pancreatoduodenectomy (EUROPA): a randomised controlled stage 2b trial". The Lancet Regional Health – Europe, 2024; 39:100864. doi: 10.1016/j.lanepe.2024.100864 (Open Access)

Awards, grants

2022 Preis "Beste Lehre im PJ" Universität Ulm

since 04/2021 Fellow of the European Board of Surgeons (FEBS, Surgical Oncology)

2019 Ars legendi Fakultätenpreis Medizin des medizinischen Fakultätentags

2012 Nachwuchslehrpreis der Medizinischen Fakultät der TU München

1998 - 2005 Stipendiat der Studienstiftung des deutschen Volkes

Curriculum Vitae – Prof. Dr. Carston Eickhoff

Personal Data

Title	Prof. Dr.
First name	Carsten
Name	Eickhoff
Current position	Professor (W3) and Director
Current institution(s)/site(s), country	University of Tübingen, Germany
Identifiers/ORCID	https://orcid.org/0000-0001-9895-4061

Qualifications and Career

Stages	Periods and Details
Degree programs	2005 - 2008 Dipl. Inf. (FH), FHDW Hannover, Hannover, Germany 2008 - 2009 M.Sc. (Artificial Intelligence), The University of Edinburgh, UK
Doctorate	2009 – 201414.10.2014, advisor: Arjen P. de Vries, subject: “Contextual Multidimensional Relevance Models” TU Delft, Faculty of EEMCS, Delft, The Netherlands
Stages of academic/professional Career	since 2022 Professor (W3) and Director, Institute for Applied Medical Informatics, University of Tübingen since 2022 Scientific Director, Medical Data Integration Center (meDIC), Tübingen University Hospital since 2022 Adjunct Professor, Brown University, USA 2018 - 2022 Manning Assistant Professor, Brown University, USA 2017 Visiting Fellow, School of Medicine, Harvard University, USA 2014 - 2017 Postdoc, Department of Computer Science, ETH Zurich, Switzerland

Activities in the Research System

Positions

2025 - 2028	Steering Committee Member, ACM ICTIR
2022 - 2025	Treasurer, ACM SIGIR
2023	Award Selection Committee Member, ECIR
2022	Reproducibility Track Chair, ECIR
2020 - now	Steering Committee Member, CLEF
2020 - now	Senior Program Committee Member, ECIR
2020	Co-Chair, CLEF Labs Organizing Committee
2019	Doctoral Consortium Chair, ACM WSDM
2018	Doctoral Consortium Chair, AAAI HCOMP
2018	Proceedings Chair, ACM SIGIR
2017 - now	Senior Program Committee Member, ACM SIGIR
2016 - now	Senior Program Committee Member, ACM WSDM

Teaching

2024 – now	Understanding Language Models, University of Tübingen
------------	---

2023 – now Introduction to Artificial Intelligence, University of Tübingen
 2023 – now Modern Search Engines, University of Tübingen
 2023 – now Natural Language Processing, University of Tübingen
 2019 – 2021 AI in Biomedicine, Brown University
 2016 – 2017 Advanced Topics in IR & NLP, ETH Zurich
 2016 Machine Learning, ETH Zurich
 2014 – 2016 Research in Computer Science, ETH Zurich

Panels (selected)

- German Research Foundation (DFG)
- US National Science Foundation (NSF)
- Swiss National Science Foundation (SNSF)
- European Commission (EC)

Supervision of Researchers in Early Career Phases

Dissertation Projects

2025 – now Miriam Rateike
 2024 – now Siran Li
 2024 – now Gregory Polyakov
 2023 – now Florian Rottach
 2021 – now Michal Golovanevsky
 2021 – now Catherine Chen
 2021 – now Tasallah Abdullahi
 2020 – now Ruochen Zhang
 2020 – 2025 William Rudman Jr. (Postdoc at UT Austin, title of dissertation: “Geometric Foundations of Large Language Model Representations”)
 2020 – 2025 John Merullo (Research Scientist at Goodfire Inc., title of dissertation: “Simple Mechanisms Underlying Complex Behaviors in Transformer Language Models”)
 2019 – 2023 Georgios Zerveas (Senior Applied Scientist at Microsoft Turing, title of dissertation: “Improving Information Retrieval through Contextual Ranking with Large Language Models”)
 2019 – 2022 Krishna Nand Keshava Murthy (Data Scientist at Memorial Sloan Kettering Cancer Center, title of dissertation: “Knowledge Informed AI Solutions for Computer Assisted Radiology”)
 2018 – 2021 Zhizhong Chen (Software Engineer at Twitter, title of dissertation: “Data-Driven Reasoning for Personalized Healthcare Mortality Forecasting & Physics-Inspired Information Retrieval Systems”)

Postdocs

2024 – now Shresta Ghosh
 2020 – now Seyed Ali Bahrainian
 2020 – 2023 Augusto Garcia-Agundez (Postdoc at UCSF)
 2020 – 2022 Daniel Cohen (Senior Research Scientist at DataMinr)

Clinician Scientists

2021 – 2022 Joshua Kemp (Assistant Professor at Brown University)
 2021 – 2022 Taylor Burke (Assistant Professor at Harvard University)
 2020 – 2022 Maya Vadiveloo (Associate Professor at the University of Rhode Island)

Fellowships mentored

- 2022 – 2026 Tassallah Abdullahi, Computational & Data Science Fellowship. ACM SIGHPC, \$60,000
- 2022 – 2023 Kevin Du, Fulbright Research Award. U.S. Department of State, \$24,000
- 2022 – 2023 Joshua Kemp, AdvanceCTR Pilot. National Institutes of Health, \$37,430
- 2021 – 2026 Taylor Burke, NIH/NIMH K23. National Institutes of Health, \$978,240
- 2022 – 2025 Augusto Garcia-Agundez, (Marie Skłodowska-Curie Fellowship). European Commission, € 245,732
- 2020 – 2021 Seyed Ali Bahreinian, Early Postdoc Mobility Fellowship. Swiss National Science Foundation (SNSF), CHF 75,450
- 2019 – 2020 Yuanfei Dai, Chinese Government Scholarship. China Scholarship Council (CSC), \$30,000

Scientific Results

Category A

* First author, ** senior author, [OA]: open access

1. ** Rudman W, **Eickhoff C**. “Stable Anisotropic Regularization”.
In Proceedings of ICLR, 2024; doi: 10.48550/arXiv.2305.19358
2. ** Chen C, Merullo J, **Eickhoff C**. “Axiomatic Causal Interventions for Reverse Engineering Relevance Computation in Neural Retrieval Models”.
In Proceedings of ACM SIGIR. 2021. doi: 10.1145/3626772.3657841
3. ** Zerveas G, Jayaraman S, Patel D, Bhamidipaty A, **Eickhoff C**. “A transformer-based framework for multivariate time series representation learning”.
In Proceedings of ACM SIGKDD, 2021; doi: 10.1145/3447548.3467401
4. ** Cohen D, Mitra B, Lesota O, Rekabsaz N, **Eickhoff C**. “Not all relevance scores are equal: Efficient uncertainty and calibration modeling for deep retrieval models”.
In Proceedings of ACM SIGIR, 2021; doi: 10.1145/3404835.3462951
5. ** Rekabsaz N, Lesota O, Schedl M, Brassey J, **Eickhoff C**. “TripClick: The log files of a large health web search engine”.
In Proceedings of ACM SIGIR, 2021; doi: 10.1145/3404835.3463242
6. Rank N, Pfahringer B, Kempfert J, Stamm C, Kühne T, Schoenrath F, Falk V, **Eickhoff C**, Meyer A. “Deep-learning-based real-time prediction of acute kidney injury outperforms human predictive performance”.
NPJ digital medicine, 2020; doi: 10.1038/s41746-020-00346-8)
7. ** Meyer A, Zverinski D, Pfahringer B, Kempfert J, Kuehne T, Sündermann SH, Stamm C, Hofmann T, Falk V, **Eickhoff C**. “Machine learning for real-time prediction of complications in critical care: A retrospective study”.
The Lancet Respiratory Medicine. 2018. doi: 10.1016/S2213-2600(18)30300-X
8. ** **Eickhoff C**. “Cognitive biases in crowdsourcing”.
In Proceedings of the 11th ACM international conference on web search and data mining. 2018; doi: 10.1145/3159652.3159654
9. * **Eickhoff C**, Dungs S, Tran V. “An eye-tracking study of query reformulation”.
In Proceedings of ACM SIGIR, 2015; doi: 10.1145/2766462.2767703

10. * **Eickhoff C**, Harris CG, de Vries AP, Srinivasan P. "Quality through flow and immersion: Gamifying crowdsourced relevance assessments".
In Proceedings of ACM SIGIR, 2012; doi: 10.1145/2348283.2348400

Academic Distinctions (selected)

2024	Computer Science Departmental Teaching Award (University of Tübingen)
2022	Best Paper Award, IEEE Intl. Conf. on Machine Learning and Applications
2022 – 2025	Treasurer, ACM Special Interest Group on Information Retrieval (SIGIR)
2022	Manning Endowed Chair of Medical Science, Brown University, USA
2019	Best Short Paper Award, European Conference on Information Retrieval
2019	Karen T. Romer Undergraduate Research & Teaching Award
2015	Best Paper Honorable Mention, ACM SIGIR